Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Over 100 posts by our resident bashing team in the last week

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 15, 2024 7:28pm

76 Views

Post# 36315995

RE:RE:Over 100 posts by our resident bashing team in the last week

Bracelet-1 successfully repeated and validated the results of IND-213 Phase 2 clinical study.

Now ONCY is preparing to run a registration study that will seek an Accelerated Approval for pelareorep in mBC.

Furthermore GCAR will be running an adaptive registration enabling study in pancreatic cancer involving pelareorep in two treatment combinations with/without folfirinox.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario